[Sulpiride treatment of irritable colon syndrome].
A blind placebo-controlled randomized trial was made of efficiency and safety of sulpirid compared to basic treatment in irritable colon syndrome (ICS). 40 patients over 18 years with ICS were randomized into two groups. Group 1 patients received sulpirid monotherapy (200-450 mg/day). Group 2 received basic therapy (combined treatment with spasmolytic, bacterial and cholagogic drugs). The treatment took 6 weeks. It was proved that sulpirid is more effective in ICS as it reduced the syndrome by 85% (basic therapy by 10%), relieved abdominalgia, anxiety, depression, corrected stool. As to disbacteriosis, sulpirid effect was weak. Tolerance of treatment in both groups was good. Side effects developed in 15% of group 1 patients and were easily corrected by lowering of the daily dose.
Komarov
F I
FI
Rapoport
S I
SI
Ivanov
S V
SV
Kharaian
L V
LV
Kolesnikov
D B
DB
Kurikov
A V
AV
D000293:Adolescent; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D012449:Safety; D013469:Sulpiride / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D002756:Cholagogues and Choleretics; D010276:Parasympatholytics; D013469:Sulpiride